Want to see AU:ILA full AI Analyst Report?
ILA Stock Chart & Stats
AU$0.44
<AU$0.01(1.25%)
At close: 4:00 PM EDT
AU$0.44
<AU$0.01(1.25%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$0.63
Previous CloseN/A
Volume241.31K
Average Volume (3M)176.37K
Market Cap
AU$116.96M
Enterprise ValueAU$99.58
Total Cash (Recent Filing)AU$12.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.59
Next Earnings
Mar 03, 2027EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding296,096,680
10 Day Avg. Volume213,821
30 Day Avg. Volume176,372
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)7.63
Price to Sales (P/S)0.00
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt materially limits interest and refinancing pressure, giving the company greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued research investment and reduces near-term solvency risk while programs remain pre-commercial.
Higher Equity BaseThe enlarged equity base strengthens the balance sheet and may support operating liquidity as the company advances its development programs. Greater capitalization provides more capacity to absorb ongoing losses, although its durability depends on future cash consumption and funding access.
Focused Antiviral StrategyA defined focus on small-molecule antivirals gives Island Pharmaceuticals a coherent development direction centered on infectious-disease needs. If programs progress, this specialization can concentrate R&D resources and create a clearer path toward commercializing internally developed therapies.
Bears Say
Minimal Revenue BaseThe absence of reported revenue in FY2026 leaves the company without a demonstrated commercial earnings base. This increases dependence on successful development outcomes before meaningful operating income can emerge and makes financial performance highly sensitive to pipeline progress.
Widening LossesWidening operating and net losses indicate that current spending substantially exceeds the limited revenue generated by the business. Persistent negative profitability can erode equity over time and raises the amount of capital required to reach potential commercialization.
Persistent Cash BurnOngoing operating and free-cash-flow outflows show that R&D and operations are not self-funding. Continued burn increases reliance on external capital to sustain development, creating funding requirements that could constrain the pace of investment if financing becomes less available.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.31 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$116.96M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Mar 03, 2027 which is in 153 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Aug 26, 2026. The company reported -AU$0.012 earnings per share for the quarter.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.02.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 296,096,680 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.012 in its last earnings report. Following the earnings report the stock price went down -1.075%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach. Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement. In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army. Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
Technical Analysis
Actinogen Medical
―
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―